NextGen Biomed (XTAE:NXGN) COGS-to-Revenue : 0.00 (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed COGS-to-Revenue?

NextGen Biomed's Cost of Goods Sold for the six months ended in Jun. 2023 was ₪0.00 Mil. Its Revenue for the six months ended in Jun. 2023 was ₪0.00 Mil.

NextGen Biomed's COGS to Revenue for the six months ended in Jun. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NextGen Biomed's Gross Margin % for the six months ended in Jun. 2023 was N/A%.

NextGen Biomed COGS-to-Revenue Historical Data

The historical data trend for NextGen Biomed's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed COGS-to-Revenue Chart

NextGen Biomed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

NextGen Biomed Semi-Annual Data
	Dec13	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
COGS-to-Revenue	Get a 7-Day Free Trial													-	-	-	-	-

NextGen Biomed COGS-to-Revenue Calculation

NextGen Biomed's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

NextGen Biomed's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

NextGen Biomed (XTAE:NXGN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NextGen Biomed's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

NextGen Biomed COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NextGen Biomed (XTAE:NXGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101

Website

http://www.nextgen-biomed.com

NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.